SUMO Biosciences is developing a small molecule drug to inhibit the major oncogene c-Myc active in human cancers. This major oncogene contributes to approximately 70% of all human cancers (e.g., colorectal, breast, prostate and lung cancers), but there is not yet a drug available that effectively inhibits c-Myc.

The small ubiquitin-like modification (SUMO) pathway is critical to c-Myc dependent oncogenesis. SUMO Biosciences has identified a novel allosteric mechanism to inhibit the activating enzymes of ubiquitin-like modifications and has identified small molecule inhibitors that use this mechanism to inhibit the SUMO activating enzyme. Early studies have demonstrated proof-of-concept in animal models for this novel target.

For more information contact: Yuan Chen, Ph D
sumobio.com